Progress development of the DNDI-6899 (GSK899/DDD853651) compound for leishmaniasis
current phase of drug development
updated 1 Mar 2023
In April 2017, DNDi and GSK entered into an agreement for the pre-clinical development of two compounds for leishmaniasis: DNDi-6899 (formerly GSK899/DDD853651) and GSK245 (DDD1305143) (formerly GSK899/DDD853651). The compounds were developed through a collaboration between the GSK Global Health Unit and the Drug Discovery Unit at the University of Dundee, with co-funding support from Wellcome. In February 2020, DNDi and GSK signed a development and license agreement for DNDI-6899.
Get our latest news, personal stories, research articles, and job opportunities.